Shots:

• The approval is based on the CANVAS program i.e. CANVAS & CANVAS-R study assessing Invokana vs PBO in 10-142 adults with T2D who have or are at risk of CV diseases
• CANVAS program results: combined MACE reduction 14% on separate bases (13%- 15% & 10%); 33% reduction in hospitalization & 30% reduction in death or hospitalization due to heart failure; mean fall in eGFR; risk of amputation ((0.59-0.75)/100 vs (0.28-0.42)/100) patient-years
• Invokana is an PO qd SGLT2i- indicated for lowering blood glucose (sugar) levels in adults with T2D and is approved by Health Canada as monotx or + antihyperglycemic agents for improving glycemic control in adult patients T2D mellitus

Ref: PRNewswire| Image: Janssen